What is the significance of the FDA's approval of mFLUSIVA?

The FDA's approval of mFLUSIVA marks the first-ever authorization of an influenza vaccine based on messenger RNA (mRNA) technology, representing a major milestone in modernizing flu vaccine development and production. As stated by Moderna CEO Stéphane Bancel, this approval is 'an important step toward a more modern approach' to addressing influenza, a longstanding public health priority. The vaccine is indicated for US adults aged 50 and older and is scheduled for availability during the 2026–27 flu season.

Who is eligible to receive mFLUSIVA and when will it be available?

According to Moderna's statement, mFLUSIVA will be available to US adults aged 50 and older for the 2026–27 flu season. This age-based eligibility reflects the initial regulatory authorization and target population for the vaccine’s rollout, as confirmed by the FDA’s first-ever approval of an mRNA-based influenza vaccine.

US FDA Approves First mRNA Flu Vaccine

Aug 7, 2026

The FDA approved Moderna's mFLUSIVA, the first mRNA-based influenza vaccine, for US adults aged 50 and older in the 2026–27 flu season. This milestone marks a key modernization step in vaccine development per Moderna CEO Stéphane Bancel.

cen

2026-08-07

US FDA Approves First mRNA Flu Vaccine

US FDA Approves First mRNA Flu Vaccine

FAQ